RNL 2022: Rheumatoid Arthritis - Best Management

Save

This week's Tuesday Night Rheumatology, hosted by Dr. Jack Cush, featured highlights from the 2022 RheumNow Live Rheumatoid Arthritis - Best Management Pod, followed by a lively audience Q & A. Lectures featured:

Recommendations – Good & Bad (5.27.2022)

Save

Dr. Jack Cush reviews the news, regulatory updates and journal reports from the past week on RheumNow.com. This week gout worries, mortality risks, measuring anti-drug antibodies and a better way in lupus?

Increasing Corticosteroid Use in Non-Hospitalized COVID-19

Save

JAMA reports that despite NIH recommendations (that corticosteroids only be used in hospitalized COVID-19 patients), nonhospitalized COVID infected patients were oftent prescribed systemic corticosteroids.

Is Gout Protective Against Dementia?

Save

People with gout appeared less likely to develop dementia than age- and sex-matched peers, a database study from Korea found.

To TDM or Not in Rheumatology?

Save

Therapeutic Drug Monitoring (TDM), especially for biologic therapies, has become a standard in gastroenterology, but shunned by most rheumatologists.

Can SGLT2 Inhibitors Be Protective in Lupus and Vasculitis?

Save

SGLT2 inhibitors are all the buzz in the renal world with reports of a renal protective and mortality lowering effects. Maybe these agents should be considered and studied in lupus nephritis and ANCA- associated vasculitis.

Amitriptyline and FDA Treatments for Fibromyalgia

Save

Both old and newer pharmacological treatments for fibromyalgia are often promoted; but a recent systematic review and network meta-analysis showed that duloxetine had higher efficacy in pain and depression, while amitriptyline had higher efficacy in treating sleep, fatigue, and quality of life outcomes.

The Inflammation Reflex (5.20.2022)

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week, neuroimmunology leading to therapy, the cold shoulder approach and Regulatory updates from the FDA.

Biologic Persistence in Psoriatic Arthritis and Psoriasis

Save

Two recent studies examined the durability and persistence of biologic agents in patients with psoriasis (PSO) and psoriatic arthritis (PsA) and while some differences were noted overall persistence was low 3 years later.

RNL 2022: Spondyloarthritis Spectrum

Save

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.

- Microbiome in Spondyloathritis - Jose Scher, MD

- Axial Psoriatic Arthritis - Philip Mease, MD

- Juvenile Spondyloathritis - Pamela Weiss, MD

Multimorbidity Burden in Rheumatoid Arthritis

Save

Crowson and colleagues at the Mayo Clinic have shown that rheumatoid arthritis (RA) patients have a higher prevalence of multimorbidity with as many as 44 different morbidities of interest in RA.

Acute Inflammatory Responses Needed to Resolve Chronic Pain

Save

Science Translational Medicine has published results of a Canadian study of low back pain (LBP) suggests that pain control by anti-inflammatory treatments might have negative effects on pain duration and may be counterproductive for long-term pain outcomes.

Bimekizumab Development Delayed by FDA

Save

UCB announced they have received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis (PSO).